Significant Shift in U.S. Cannabis Policy
Recently, President Donald Trump signed an executive order aimed at changing how the U.S. classifies marijuana. This decision is seen as the biggest change in cannabis policy in over 50 years. The move directs federal agencies to consider placing cannabis in a less restrictive category—Schedule III—under the Controlled Substances Act. This classification includes drugs like ketamine and Tylenol with codeine, which are regarded as having medical use with a lower potential for abuse.
In his announcement, Trump highlighted the need for this change: “This action has been requested by American patients suffering from extreme pain, incurable diseases, and chronic medical problems.” These changes could help veterans and older Americans who are living with debilitating conditions.
Furthermore, the Centers for Medicare and Medicaid Services plans to launch a pilot program in April. This program would allow certain seniors covered by Medicare to access doctor-recommended CBD products at no cost. These products will need to comply with safety and quality regulations and be tested for quality.
Stock prices for major cannabis companies dipped after the announcement. Companies like Trulieve and Green Thumb Industries saw significant declines. Some speculate that this is due to fears of increased competition from international markets.
Ben Kovler, CEO of Green Thumb, expressed optimism about the changes. “Millions of patients rely on cannabis for relief,” he stated. “We commend the administration for taking this historic step. This is only the beginning.”
This reclassification could also provide financial relief for cannabis companies. It allows them to deduct standard business expenses like rent and payroll, something previously restricted under IRS Code Section 280E. Analysts believe this change may attract big pharmaceutical companies into the cannabis sector, especially as the Medicare pilot aims to capture federally insured revenue.
While interest in CBD products has grown significantly, the FDA has not fully endorsed CBD, citing concerns over inconsistent benefits and potential health risks linked to long-term use. As of now, the FDA has only approved a single CBD-based medication, Epidiolex, which treats rare forms of epilepsy.
Experts believe that this reclassification will encourage more research into CBD and its effects. As the landscape of cannabis policy transforms, both industry insiders and consumers are keeping a close eye on future developments.
For more detailed information on the implications of this policy change, you can refer to this report from the National Institute of Health.
Source link
Breaking News: Business,Health care industry,Politics,Breaking News: Politics,Business,Cronos Group Inc,Cronos Group Inc,Synthetic marijuana,Drug use,Pharmaceuticals,Biotechnology,Medical research,Health,U.S. Department of Health and Human Services,U.S. Drug Enforcement Administration,Investment strategy,Stock markets,Marijuana,Nasdaq Inc,AdvisorShares Pure US Cannabis ETF,Social issues,Donald Trump,Green Thumb Industries Inc,Tilray Brands Inc,Tilray Brands Inc,Trulieve Cannabis Corp,Donald J. Trump,business news
